The document describes CarTarDis, a 4-year public-private partnership with 13 partners from 8 countries and a budget of 8.0M Euros that began on October 1, 2013. The project aims to discover novel cardiovascular drug targets through a strong interdisciplinary team with expertise in cardiovascular disease biology, drug discovery, translational medicine, omics technologies, and more. CarTarDis will utilize unique human cohort data, biobanks, CVD models and samples to generate a candidate target database, review targets, validate a shortlist, and create online dossiers to share knowledge on selected targets. The goal is to prioritize 11 targets for further validation activities to identify new treatments for cardiovascular disease.

1. CarTarDis
Cardiovascular Target Discovery
EU FP7 Health call 2013
CarTarDis
www.cartardis.eu

2. Discovery of novel cardiovascular drug targets
CarTarDis = Cardiovascular Target Discovery
Public-private partnership, 13 partners, 8 countries, project budget 8.0M Eur
Start 1 Oct 2013 for 4 years
(Coordinator)
CarTarDis

3. Discovery of novel cardiovascular drug targets
(Coordinator)
CarTarDis
A strong interdisciplinary team of experts in:
Cardiovascular disease biology, drug discovery processes, translational medicine,
population studies, Omics, imaging, bioinformatics, applied technology
CarTarDis = Cardiovascular Target Discovery
Public-private partnership (4 years)
Project budget 8.0M Eur
Start 1 Oct 2013
13 partners from 8 countries: research-driven SME’s, universities,
research & technology institutes, large pharma

4. Unique cohort and sample data
CarTarDis
A global network of human
cohort study data, biobanks
and clinical scientists.

5. Unique translational CVD models
CarTarDis
CVD mouse CVD patient
CVD mouse and cellular models
used in >200 studies.
Intensive phenotyping and
molecular analyses.

6. Unique CVD samples
CarTarDis
Unique human biobanks with
samples across the cardiovascular
disease spectrum.

7. Unique molecular detection methods
CarTarDis
Immunohistochemistry
(protein)
In situ hybridisation
(miRNA, mRNA)
MS Imaging
(lipids, metabolites)
Human/mouse
CVD samples
Laser capture microdissection
+ targeted omics (RNA, proteins)
Histology

8. Rational framework for target selection
The 5R’s assessment:
• Right Target
• Right Tissue
• Right Safety
• Right Patients
• Right Commercial Potential
CarTarDis

9. Target identification & selection process
CarTarDis
1. Generate a comprehensive candidate target database
• GWAS, literature, proprietary
2. Review all candidate targets
• Automatic scoring
• Expert review
3. Rank targets (following 5R’s)
• 1. Drugability
• 2. Novelty
• 3. Omics/genetics
• 4. Feasibility (within CarTarDis)
• 5. Pathways (expertise within CarTarDis)
4. Select shortlist of candidate targets for validation

10. Target View: web interface
CarTarDis
http://146.107.41.240/db/CarTarDisApp/
GWAS cohort data 302
Other literature 43
Partners research 35
Total: 380

11. Target View: Details about each target
• Annotations
• Cross references
• Auto-collected data
• Reviewed data from
publications
• Hyperlinks to public
databases (PubMed, GWAS,
proteinatlas, etc)
• Personal comments by
experts
Ordered by ‚Target Name‘
CarTarDis

12. CarTarDis target reviewing process
CarTarDis
• Build and improve database as central knowledge base (month 3)
• Decide on target prioritisation criteria and review procedure (month 6)
• Fill database and apply automated scoring (month 6-12)
• Discussed during various live target review jamborees (months 6, 12)
• Off line expert reviewing in small groups (email, telephone)
• Finish target selection during selection meeting (month 14)
• Prioritise targets for validation activities (month 18)
• Draft target validation plans (month 14-18)
380 candidate targets → 23 pre-selected targets → 11 selected targets

13. CarTarDis target evaluation dossiers
CarTarDis
Knowledge sharing using Google Sites
All
selected
targets
Potential drug target
Links to
target
information
in external
databases
• Target summary - key points of pro’s and con’s of the candidate target
• Target details - description, relevant data, selection scores following 5R’s criteria
• Gap analysis - lacking data
• Validation planning - directing activities in WP1, WP2, WP3
• References - relevant literature

14. CarTarDis on www CarTarDis

15. CarTarDis website
CarTarDis
www.cartardis.eu